Trade Practices & Advertising (FTC)

Dockets

• Requests that the FDA refrain from approving any ANDA submitted pursuant to an approved suitability petition under section 505(j)(2)(C) of the FD&C Act for dabrafenib mesylate capsules, 150 mg (EQ Base), unless and until the applicant has conducted and submitted to the FDA.FDAOpen
  24 docs · 0 comments
• FTC Seek Comments on Generic Clearance for Service Delivery, Paperwork Reduction Act Comment, OMB No. 3084-0159FTC
  1 docs · 0 comments